The_DT Moloney_NP Murine_NP Leukemia_NP Virus_NP Repressor_NP Binding_NP Site_NP Represses_NP Expression_NP in_IN Murine_NP and_CC Human_NP Hematopoietic_NP Stem_NP Cells_NP The_DT Moloney_NP murine_JJ leukemia_NN virus_NN (_( MLV_NP )_) repressor_NN binding_VBG site_NN (_( RBS_NN )_) is_VBZ a_DT major_JJ determinant_NN of_IN restricted_JJ expression_NN of_IN MLV_NP in_IN undifferentiated_JJ mouse_NN embryonic_JJ stem_NN (_( ES_NP )_) cells_NNS and_CC mouse_NN embryonal_JJ carcinoma_NN (_( EC_NP )_) lines_NNS ._SENT We_PP show_VBP here_RB that_IN the_DT RBS_JJ repressed_JJ expression_NN when_WRB placed_VBN outside_IN of_IN its_PP$ normal_JJ MLV_NP genome_NN context_NN in_IN a_DT self-inactivating_JJ (_( SIN_JJ )_) lentiviral_JJ vector_NN ._SENT In_IN the_DT lentiviral_JJ vector_NN genome_NN context_NN ,_, the_DT RBS_JJ repressed_JJ expression_NN of_IN a_DT modified_JJ MLV_NP long_JJ terminal_NN repeat_NN (_( MNDU3_NP )_) promoter_NN ,_, a_DT simian_JJ virus_NN 40_CD promoter_NN ,_, and_CC three_CD cellular_JJ promoters_NNS :_: ubiquitin_NP C_NP ,_, mPGK_NN ,_, and_CC hEF-1a_NN ._SENT In_IN addition_NN to_TO repressing_VBG expression_NN in_IN undifferentiated_JJ ES_NP and_CC EC_NP cell_NN lines_NNS ,_, we_PP show_VBP that_IN the_DT RBS_NN substantially_RB repressed_VBN expression_NN in_IN primary_JJ mouse_NN embryonic_JJ fibroblasts_NNS ,_, primary_JJ mouse_NN bone_NN marrow_NN stromal_JJ cells_NNS ,_, whole_JJ mouse_NN bone_NN marrow_NN and_CC its_PP$ differentiated_VBN progeny_NN after_IN bone_NN marrow_NN transplant_NN ,_, and_CC several_JJ mouse_NN hematopoietic_JJ cell_NN lines_NNS ._SENT Using_VBG an_DT electrophoretic_JJ mobility_NN shift_NN assay_NN ,_, we_PP show_VBP that_IN binding_JJ factor_NN A_NP ,_, the_DT trans-acting_NN factor_NN proposed_VBN to_TO convey_VB repression_NN by_IN its_PP$ interaction_NN with_IN the_DT RBS_NN ,_, is_VBZ present_JJ in_IN the_DT nuclear_JJ extracts_VBZ of_IN all_DT mouse_NN cells_NNS we_PP analyzed_VBD where_WRB expression_NN was_VBD repressed_VBN by_IN the_DT RBS_NN ._SENT In_IN addition_NN ,_, we_PP show_VBP that_IN the_DT RBS_NN partially_RB repressed_VBN expression_NN in_IN the_DT human_JJ hematopoietic_JJ cell_NN line_NN DU.528_NP and_CC primary_JJ human_JJ CD34+_NP CD38-_NP hematopoietic_JJ cells_NNS isolated_VBN from_IN umbilical_JJ cord_NN blood_NN ._SENT These_DT findings_NNS suggest_VBP that_IN retroviral_JJ vectors_NNS carrying_VBG the_DT RBS_NN are_VBP subjected_VBN to_TO high_JJ rates_NNS of_IN repression_NN in_IN murine_JJ and_CC human_JJ cells_NNS and_CC that_IN MLV_NP vectors_NNS with_IN primer_JJR binding_JJ site_NN substitutions_NNS that_WDT remove_VB the_DT RBS_NN may_MD yield_VB more-effective_JJ gene_NN expression_NN ._SENT Retroviral_JJ vectors_NNS based_VBN upon_IN the_DT Moloney_NP murine_JJ leukemia_NN virus_NN (_( MLV_NP )_) have_VBP been_VBN used_VBN widely_RB due_JJ to_TO their_PP$ high_JJ efficiency_NN of_IN stable_JJ gene_NN transfer_NN ._SENT Transcription_NN from_IN the_DT MLV_NP long_JJ terminal_NN repeat_NN (_( LTR_NP )_) is_VBZ severely_RB repressed_VBN in_IN mouse_NN embryonal_JJ carcinoma_NN (_( EC_NP )_) cells_NNS and_CC mouse_NN embryonal_JJ stem_NN (_( ES_NP )_) cells_NNS ._SENT Characteristics_NNS of_IN MLV_NP that_WDT have_VBP been_VBN shown_VBN to_TO mediate_VB poor_JJ expression_NN in_IN undifferentiated_JJ ES_NP and_CC EC_NP cell_NN lines_NNS include_VBP the_DT inadequate_JJ function_NN of_IN the_DT enhancer_NN in_IN the_DT 5'LTR_NN due_JJ to_TO the_DT lack_NN of_IN transcriptional_JJ activator_NN binding_VBG sites_NNS ,_, the_DT negative_JJ control_NN region_NN (_( NCR_NP )_) located_VBN in_IN the_DT U3_NP region_NN of_IN the_DT LTR_NP ,_, and_CC the_DT repressor_NN binding_VBG site_NN (_( RBS_NP )_) ._SENT The_DT RBS_NN is_VBZ an_DT 18-bp_JJ DNA_NN element_NN located_VBN downstream_RB of_IN the_DT 5'LTR_NN which_WDT directly_RB overlaps_VBZ the_DT MLV_NP primer_NN binding_VBG site_NN (_( PBS_NP )_) by_IN 17_CD of_IN its_PP$ 18_CD bp_NN ._SENT The_DT MLV_NP PBS_NP functions_NNS by_IN binding_VBG a_DT proline_NN tRNA_NN molecule_NN that_WDT primes_VBZ reverse_JJ transcription_NN ._SENT The_DT existence_NN of_IN the_DT overlapping_JJ RBS_NN was_VBD first_RB determined_VBN due_JJ to_TO a_DT spontaneously_RB occurring_VBG single-base_JJ G-to-A_NP mutation_NN that_WDT occurred_VBD within_IN the_DT PBS_NP sequence_NN that_WDT allowed_VBD expression_NN by_IN MLV_NP in_IN F9_NP EC_NP cells_NNS ._SENT This_DT single_JJ base_NN mutation_NN was_VBD called_VBN the_DT B2_JJ mutation_NN ._SENT Like_IN the_DT MLV_NP PBS_NP ,_, the_DT B2_JJ PBS_NP binds_NNS to_TO a_DT proline_NN tRNA_NN molecule_NN ,_, but_CC with_IN a_DT single_JJ base-pair_NN mismatch_NN ._SENT Several_JJ other_JJ mutations_NNS that_WDT have_VBP been_VBN made_VBN within_IN the_DT MLV_NP PBS_NP have_VBP also_RB been_VBN shown_VBN to_TO relieve_VB the_DT repression_NN conveyed_VBD by_IN the_DT RBS_JJ element_NN ._SENT Due_JJ to_TO the_DT requirement_NN that_WDT vectors_VBZ derived_VBN from_IN MLV_NP must_MD contain_VB a_DT functional_JJ PBS_NP to_TO initiate_VB reverse_JJ transcription_NN ,_, the_DT overlapping_JJ RBS_NN sequence_NN cannot_MD be_VB removed_VBN simply_RB by_IN removing_VBG the_DT MLV_NP PBS_NP ._SENT In_IN order_NN to_TO eliminate_VB this_DT repressive_JJ element_NN and_CC still_RB have_VB a_DT functional_JJ vector_NN ,_, several_JJ groups_NNS have_VBP replaced_VBN the_DT MLV_NP PBS_NP with_IN the_DT PBS_NP from_IN dl587rev_NP ,_, a_DT recombinant_JJ between_IN MLV_NP and_CC an_DT endogenous_JJ mouse_NN retrovirus_NN ._SENT The_DT dl587rev_NP PBS_NP sequence_NN contains_VBZ the_DT B2_JJ mutation_NN plus_CC five_CD additional_JJ base_NN pairs_NNS different_JJ from_IN the_DT MLV_NP PBS_NP and_CC is_VBZ a_DT perfect_JJ match_NN for_IN the_DT glutamine_NN tRNA_NN ._SENT The_DT RBS_NN has_VBZ been_VBN shown_VBN to_TO repress_VB transcription_NN from_IN the_DT MLV_NP LTR_NP within_IN the_DT context_NN of_IN an_DT MLV_NP genome_NN when_WRB located_VBN away_RB from_IN its_PP$ normal_JJ position_NN ,_, in_IN either_DT orientation_NN ,_, upstream_RB of_IN the_DT MLV_NP transcription_NN start_NN site_NN or_CC when_WRB positioned_VBN downstream_RB within_IN an_DT intron_NN ._SENT In_IN addition_NN to_TO repressing_VBG transcription_NN from_IN the_DT MLV_NP LTR_NP ,_, the_DT RBS_NN was_VBD shown_VBN to_TO substantially_RB repress_VB transcription_NN from_IN two_CD internal_JJ heterologous_JJ viral_JJ promoters_NNS ,_, simian_JJ virus_NN 40_CD (_( SV40_NP )_) and_CC adenovirus_NN major_JJ late_JJ promoter_NN ,_, which_WDT were_VBD inserted_VBN downstream_RB of_IN the_DT RBS_NN into_IN an_DT MLV_NP vector_NN with_IN an_DT enhancerless_JJ LTR_NP ._SENT The_DT mechanism_NN by_IN which_WDT the_DT RBS_NN represses_VBZ transcription_NN is_VBZ not_RB known_VBN ._SENT The_DT RBS_NN is_VBZ thought_VBN to_TO function_VB by_IN interacting_VBG with_IN an_DT unknown_JJ trans-acting_NN factor_NN ._SENT In_IN support_NN of_IN this_DT hypothesis_NN ,_, the_DT repressive_JJ activity_NN of_IN the_DT RBS_NN was_VBD demonstrated_VBN to_TO be_VB saturable_JJ by_IN transfection_NN of_IN increasing_VBG amounts_NNS of_IN DNA_NN containing_VBG the_DT RBS_JJ sequence_NN ,_, suggesting_VBG that_IN the_DT repressive_JJ activity_NN is_VBZ mediated_VBN by_IN a_DT trans-acting_NN factor_NN or_CC factors_NNS ._SENT With_IN an_DT exonuclease_NN III_NP protection_NN assay_NN ,_, a_DT factor_NN from_IN PC13_NP EC_NP cell_NN extracts_VBZ was_VBD shown_VBN to_TO bind_VB a_DT MLV_NP PBS_NP probe_NN ,_, but_CC not_RB a_DT B2_JJ PBS_NP probe_NN ._SENT Using_VBG an_DT electrophoretic_JJ mobility_NN shift_NN assay_NN (_( EMSA_NP )_) ,_, a_DT predominantly_RB nuclear_JJ protein_NN in_IN F9_NP EC_NP cell_NN nuclear_JJ extracts_VBZ was_VBD identified_VBN that_IN bound_VBN to_TO an_DT MLV_NP PBS_NP probe_NN ,_, but_CC not_RB a_DT B2_JJ PBS_NP probe_NN ._SENT Several_JJ studies_NNS have_VBP described_VBN the_DT repressive_JJ activity_NN of_IN the_DT RBS_NN to_TO be_VB stem_VB cell_NN specific_NN ,_, because_IN it_PP has_VBZ been_VBN shown_VBN to_TO have_VB repressive_JJ activity_NN in_IN several_JJ murine_JJ EC_NP cell_NN lines_NNS (_( F9_NP ,_, PC13_NP ,_, and_CC PCC4_NP )_) and_CC D3_NP ES_NP cells_NNS ,_, but_CC not_RB in_IN 3T3_JJ embryonic_JJ fibroblasts_NNS ._SENT Retroviral_JJ vectors_NNS with_IN multiple_JJ modifications_NNS ,_, including_VBG the_DT dl587rev_NP PBS_NP ,_, have_VBP been_VBN demonstrated_VBN to_TO be_VB superior_JJ to_TO vectors_NNS containing_VBG only_JJ MLV_NP components_NNS ,_, but_CC the_DT specific_JJ role_NN of_IN the_DT PBS_NP change_NN has_VBZ not_RB been_VBN analyzed_VBN ._SENT We_PP evaluated_VBD whether_IN the_DT RBS_NN alone_RB was_VBD sufficient_JJ to_TO cause_VB repression_NN by_IN incorporating_VBG this_DT element_NN into_IN a_DT lentiviral_JJ vector_NN derived_VBN from_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NP )_) ._SENT We_PP also_RB wanted_VBD to_TO determine_VB if_IN the_DT repressive_JJ activity_NN mediated_VBN by_IN the_DT RBS_JJ present_NN in_IN ES_NP and_CC EC_NP cell_NN lines_NNS was_VBD also_RB present_JJ in_IN murine_JJ hematopoietic_JJ stem_NN cells_NNS and_CC more_RBR differentiated_VBN cells_NNS and_CC if_IN the_DT repressive_JJ activity_NN mediated_VBN by_IN the_DT RBS_NN was_VBD present_JJ in_IN human_JJ cells_NNS ._SENT Because_IN some_DT of_IN these_DT cell_NN types_NNS are_VBP inefficiently_RB transduced_VBN by_IN MLV-based_JJ retroviral_JJ vectors_NNS ,_, we_PP used_VBD a_DT series_NN of_IN HIV-1-based_JJ lentiviral_JJ vectors_NNS into_IN which_WDT the_DT MLV_NP ,_, B2_NN ,_, or_CC the_DT dl587_JJ PBS_NP sequences_NNS were_VBD inserted_VBN downstream_RB from_IN various_JJ internal_JJ promoters_NNS ._SENT We_PP observed_VBD that_IN the_DT PBS_NP sequences_NNS acted_VBD in_IN the_DT context_NN of_IN the_DT lentiviral_JJ vector_NN genome_NN as_IN they_PP do_VBP within_IN the_DT MLV_NP vector_NN genome_NN context_NN in_IN that_WDT the_DT MLV_NP PBS_NP sequence_NN ,_, containing_VBG the_DT overlapping_JJ RBS_NN ,_, repressed_JJ expression_NN from_IN several_JJ internal_JJ promoters_NNS ,_, while_IN the_DT B2_JJ and_CC dl587_JJ PBS_NP sequences_NNS did_VBD not_RB ._SENT Repression_NN specific_JJ to_TO the_DT RBS_NN was_VBD also_RB documented_VBN in_IN a_DT variety_NN of_IN murine_JJ and_CC human_JJ cells_NNS ,_, including_VBG hematopoietic_JJ stem_NN and_CC progenitor_NN cells_NNS ._SENT Cell_NN culture_NN ._SENT |_SYM The_DT following_VBG cell_NN lines_NNS were_VBD obtained_VBN from_IN the_DT American_NP Type_NP Culture_NP Collection_NP (_( ATCC_NP )_) and_CC cultured_JJ according_VBG to_TO their_PP$ recommendations_NNS :_: K562_NP (_( ATCC_NP CCL-243_NP )_) ,_, U937_JJ (_( ATCC_NP CRL-1593.2_NP )_) ,_, PA-1_NP (_( ATCC_NP CRL-1572_NP )_) ,_, Tera-2_NP (_( ATCC_NP HTB-106_NP )_) ,_, NCCIT_NP (_( ATCC_NP CRL-2073_NP )_) ,_, 70Z/3_NP (_( ATCC_NP TIB-158_NP )_) ,_, STO-SNL/2_NP (_( ATCC_NP CRL-2225_NP )_) ,_, ES-D3_NP (_( ATCC_NP CRL-1934_NP )_) ,_, Jurkat_NP (_( ATCC_NP TIB-152_NP )_) ,_, KG1a_NP (_( ATCC_NP CCL-246.1_NP )_) ,_, AMJ2-C11_NP (_( ATCC_NP CRL-2456_NP )_) ,_, F9_NP EC_NP (_( ATCC_NP CRL-1720_NP )_) ,_, NIH/3T3_NP (_( ATCC_NP CRL-1658_NP )_) ,_, and_CC CCRF-CEM_NP (_( ATCC_NP CCL-119_NP )_) ._SENT DU.528_NP were_VBD obtained_VBN from_IN Joanne_NP Kurtzberg_NP (_( Duke_NP University_NP Medical_NP Center_NP ,_, Durham_NP ,_, N.C._NP )_) and_CC cultured_VBN in_IN Roswell_NP Park_NP Memorial_NP Institute_NP (_( RPMI_NP )_) 1640_CD medium_NN supplemented_VBN with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( FBS_NP )_) ,_, 10_CD %_NN horse_NN serum_NN (_( HS_NP )_) ,_, 2_CD mM_NP l-glutamine_NN ,_, 0.1_CD mM_NP sodium_NN pyruvate_NNS ,_, 100_CD U_NN of_IN penicillin/ml_NN ,_, and_CC 100_CD mug_NN of_IN streptomycin/ml_NN ._SENT BM185_NP cells_NNS have_VBP been_VBN previously_RB described_VBN and_CC were_VBD cultured_VBN in_IN RPMI_NP medium_NN supplemented_VBD with_IN 5_CD %_NN FBS_NP ,_, 0.01_CD mM_NP 2-mercaptoethanol_NP (_( Sigma_NP ,_, St._NP Louis_NP ,_, Mo._NP )_) ,_, 100_CD U_NN of_IN penicillin/ml_NN ,_, and_CC 100_CD mug_NN of_IN streptomycin/ml_NN ._SENT WTc.F_NP cells_NNS (_( ES_NP cells_NNS derived_VBN from_IN C57Bl/6_NP mice_NNS )_) ,_, a_DT gift_NN of_IN Andrew_NP Kung_NP (_( Harvard_NP Medical_NP School_NP ,_, Boston_NP ,_, Mass._NP )_) ,_, were_VBD cultured_VBN on_IN irradiated_JJ STO-SNL/2_NP feeder_NN layers_NNS in_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP 's_POS medium_NN (_( DMEM_NP )_) supplemented_VBD with_IN 15_CD %_NN FBS_NP ,_, 4_CD mM_NP l-glutamine_NN ,_, 0.1_CD mM_NP nonessential_JJ amino_NN acids_NNS ,_, 0.1_CD mM_NNS 2-mercaptoethanol_JJ ,_, 100_CD U_NN of_IN penicillin/ml_NN ,_, and_CC 100_CD mug_NN of_IN streptomycin/ml_NN ._SENT FDCP-Mix_NP cl.A4_NP was_VBD obtained_VBN from_IN Lez_NP Fairbairn_NP (_( Paterson_NP Institute_NP for_IN Cancer_NP Research_NP ,_, Manchester_NP ,_, United_NP Kingdom_NP )_) and_CC cultured_VBN in_IN Iscove_NP 's_POS modification_NN of_IN Dulbecco_NP 's_POS medium_NN (_( IMDM_NP )_) supplemented_VBD with_IN 20_CD %_NN HS_NN and_CC 10_CD ng_NNS of_IN murine_JJ interleukin-3_NN (_( IL-3_NP ;_: Biosource_NP International_NP ,_, Camarillo_NP ,_, Calif.)/ml_NP ._SENT Mouse_NP embryonic_JJ fibroblasts_NNS (_( MEFs_NP )_) were_VBD isolated_VBN by_IN trypsinization_NN of_IN embryos_NNS dissected_VBN at_IN 13.5_CD days_NNS of_IN gestation_NN from_IN outbred_VBN CF-1_JJ mice_NNS (_( Charles_NP River_NP Laboratories_NPS ,_, Wilmington_NP ,_, Mass._NP )_) ._SENT Each_DT embryo_NN was_VBD harvested_VBN separately_RB ,_, the_DT brain_NN and_CC internal_JJ organs_NNS were_VBD removed_VBN ,_, and_CC the_DT carcasses_NNS were_VBD minced_VBN and_CC incubated_VBN in_IN 0.05_CD %_NN trypsin_NN for_IN 30_CD to_TO 45_CD min_NN at_IN 37C_JJ ._SENT Single-cell_NN suspensions_NNS obtained_VBN after_IN trypsinization_NN were_VBD plated_VBN in_IN 10-cm_JJ dishes_NNS in_IN DMEM_NP supplemented_VBD with_IN 10_CD %_NN FBS_NP ,_, 100_CD U_NN of_IN penicillin/ml_NN ,_, 100_CD mug_NN of_IN streptomycin/ml_NN ,_, and_CC 2_CD mM_NP l-glutamine_NN ._SENT Experiments_NNS with_IN MEFs_NP were_VBD performed_VBN on_IN early_JJ passages_NNS (_( less_JJR than_IN five_CD )_) ._SENT Mouse_NN bone_NN marrow_NN (_( BM_NP )_) cells_NNS were_VBD isolated_VBN by_IN flushing_VBG bone_NN marrow_NN from_IN adult_JJ mouse_NN femurs_NNS with_IN a_DT 27[1/2]-gauge_JJ needle_NN ._SENT Bone_NN marrow_NN stromal_JJ cell_NN populations_NNS were_VBD isolated_VBN by_IN breaking_VBG the_DT femurs_NNS into_IN small_JJ pieces_NNS and_CC culturing_VBG them_PP with_IN isolated_JJ marrow_NN cells_NNS ._SENT Cells_NNS were_VBD allowed_VBN to_TO adhere_VB to_TO tissue_VB culture_NN plates_NNS for_IN 4_CD to_TO 6_CD days_NNS in_IN IMDM_NP containing_VBG 20_CD %_NN HS_NN ,_, 20_CD %_NN FBS_NP ,_, 2_CD mM_NP l-glutamine_NN ,_, 100_CD U_NN of_IN penicillin/ml_NN ,_, 100_CD mug_NN of_IN streptomycin/ml_NN ,_, 0.1_CD mM_NNS 2-mercaptoethanol_JJ ,_, and_CC 6_CD muM_NN hydrocortisone_NN ._SENT Adherent_JJ cells_NNS were_VBD rinsed_VBN 5_CD to_TO 7_CD times_NNS with_IN phosphate-buffered_JJ saline_NN (_( Irvine_NP Scientific_NP ,_, Santa_NP Ana_NP ,_, Calif._NP )_) every_DT day_NN for_IN 10_CD to_TO 15_CD days_NNS to_TO remove_VB nonadherent_JJ cells_NNS ._SENT Adherent_JJ cells_NNS were_VBD allowed_VBN to_TO expand_VB to_TO confluency_NN for_IN an_DT additional_JJ 2_CD to_TO 3_CD weeks_NNS ._SENT Remaining_VBG CD45+_JJ hematopoietic_JJ cells_NNS were_VBD removed_VBN with_IN a_DT magnetic_JJ column_NN after_IN staining_VBG with_IN rat_NN anti-mouse_NN CD45_NP antibody_NN and_CC magnetic_JJ bead-conjugated_JJ goat_NN anti-rat_NN immunoglobulin_NN G._NP CD45-_NP cells_NNS were_VBD placed_VBN back_RB into_IN culture_NN and_CC later_RBR verified_VBN to_TO be_VB CD45-_JJ by_IN flow_NN cytometry_NN ._SENT CD34+_NP cells_NNS were_VBD isolated_VBN from_IN human_JJ umbilical_JJ cord_NN blood_NN obtained_VBN from_IN normal_JJ deliveries_NNS ,_, using_VBG Miltenyi_NP MiniMACS_NP magnetic_JJ separation_NN columns_NNS (_( Miltenyi_NP Biotech_NP ,_, Sunnyvale_NP ,_, Calif._NP )_) after_IN Ficoll-Hypaque_NP (_( Amersham_NP Pharmacia_NP Biotech_NP ,_, Piscataway_NP ,_, N.J._NP )_) density_NN gradient_JJ centrifugation_NN ._SENT Use_NN of_IN these_DT cord_NN blood_NN samples_NNS was_VBD approved_VBN by_IN the_DT Committee_NP on_IN Clinical_JJ Investigations_NNS at_IN Childrens_NP Hospital_NP ,_, Los_NP Angeles_NP ,_, Calif._NP To_TO isolate_VB CD34+_NP CD38-_NP cells_NNS ,_, CD34+_NP cells_NNS were_VBD washed_VBN in_IN phosphate-buffered_JJ saline_NN and_CC incubated_VBN for_IN 30_CD min_NN at_IN 4C_JJ in_IN fluorescein_NN isothiocyanate-CD34_NN (_( HPCA2_NP ;_: Becton_NP Dickinson_NP Immunocytometry_NP Systems_NP ,_, San_NP Jose_NP ,_, Calif._NP )_) and_CC phycoerythrin-CD38_JJ (_( leu_NN 17_CD ;_: Becton_NP Dickinson_NP Immunocytometry_NP Systems_NPS )_) ._SENT CD34+_NP CD38-_NP cells_NNS were_VBD then_RB isolated_VBN by_IN fluorescence-activated_JJ cell_NN sorting_VBG (_( FACS_NP )_) ,_, using_VBG the_DT gating_VBG previously_RB described_VBN ,_, on_IN a_DT FACSVantage_NP flow_NN cytometer_NN (_( Becton_NP Dickinson_NP Immunocytometry_NP Systems_NPS )_) and_CC using_VBG LysysII_NP software_NN (_( Becton_NP Dickinson_NP Immunocytometry_NP Systems_NPS )_) ._SENT Vector_NN construction_NN ._SENT |_SYM The_DT pL-eGFP-SN_NN vector_NN was_VBD constructed_VBN by_IN inserting_VBG a_DT BglII-NotI_NP fragment_NN containing_VBG the_DT enhanced_JJ green_JJ fluorescent_JJ protein_NN (_( eGFP_NN )_) gene_NN (_( Clontech_NP Laboratories_NP ,_, Palo_NP Alto_NP ,_, Calif._NP )_) into_IN the_DT HpaI_NP site_NN of_IN pL-X-SN_NN as_IN previously_RB described_VBN ._SENT Modifications_NNS made_VBD to_TO pL-eGFP-SN_NN to_TO generate_VB pLD-eGFP-SN_NN ,_, pM-eGFP-SN_NP ,_, pMD-eGFP-SN_NN ,_, and_CC pMND-eGFP-SN_NNS were_VBD described_VBN previously_RB ._SENT Self-inactivating_NP (_( SIN_NP )_) lentiviral_JJ vectors_NNS containing_VBG the_DT U3_JJ region_NN of_IN the_DT MND_NP LTR_NP (_( MNDU3_NP ;_: the_DT U3_JJ region_NN from_IN the_DT myeloproliferative_JJ sarcoma_NN virus_NN [_SYM MPSV_NP ]_SYM LTR_NP with_IN the_DT NCR_NP removed_VBD )_) as_IN an_DT internal_JJ promoter_NN with_IN each_DT of_IN the_DT PBS_NP sequences_NNS were_VBD constructed_VBN as_RB follows_VBZ ._SENT pCCL-hCMV-eGFP_NP (_( kindly_RB provided_VBN by_IN Luigi_NP Naldini_NP ,_, Cell_NP Genesys_NP ,_, Foster_NP City_NP ,_, Calif._NP )_) was_VBD digested_VBN with_IN ClaI_NP and_CC SalI_NP to_TO remove_VB a_DT fragment_NN containing_VBG hCMV-eGFP_NN to_TO generate_VB pCCL-X_NN ._SENT pMND-Neo_NN was_VBD digested_VBN with_IN ClaI_NP and_CC Asc1_NP to_TO isolate_VB a_DT fragment_NN containing_VBG the_DT MNDU3_NP promoter_NN ._SENT The_DT MNDU3_NP enhancer-promoter_NN fragment_NN was_VBD blunted_VBN and_CC ligated_VBN into_IN the_DT EcoR5_NP site_NN of_IN pIC-20H_NN to_TO generate_VB pMNDU3-20H_NN ._SENT pMNDU3-20H_NN was_VBD digested_VBN with_IN BamHI_NP and_CC BglII_NP to_TO isolate_VB a_DT fragment_NN containing_VBG the_DT MNDU3_NP enhancer-promoter_NN ._SENT The_DT MNDU3_NP enhancer-promoter_NN fragment_NN was_VBD inserted_VBN into_IN the_DT BamHI_NP site_NN of_IN pCCL-X_NN to_TO generate_VB pCCL-MNDU3-X_NN ._SENT pMND-eGFP-SN_NN was_VBD digested_VBN with_IN XhoI_NP to_TO release_VB a_DT fragment_NN containing_VBG eGFP_NN ._SENT The_DT eGFP_NN fragment_NN was_VBD ligated_VBN into_IN the_DT XhoI_NP site_NN of_IN pCCL-MNDU3-X_NN to_TO generate_VB pCCL-MNDU3-eGFP_NN ._SENT The_DT MLV_NP PBS_NP was_VBD inserted_VBN into_IN the_DT SalI_NP site_NN downstream_RB of_IN the_DT MNDU3_NP promoter_NN using_VBG 5'-phosphorylated_JJ oligonucleotides_NNS which_WDT anneal_VBP to_TO create_VB the_DT PBS_NP (_( underlined_VBN )_) flanked_VBD by_IN SalI_NP sites_NNS and_CC a_DT unique_JJ MluI_NP site_NN used_VBD to_TO verify_VB insertion_NN :_: 5'-TCGACACGCGTGGGGGCTCGTCCGGGATCGGGAGACCCCG-3_NP '_POS and_CC 5'-TCGACGGGGGCTCCCGATCCCGGACGAGCCCCCACGCGTG-3_NP '_POS ._SENT The_DT B2_JJ PBS_NP was_VBD inserted_VBN into_IN the_DT SalI_NP site_NN downstream_RB of_IN the_DT MNDU3_NP promoter_NN using_VBG 5'-phosphorylated_JJ oligonucleotides_NNS which_WDT anneal_VBP to_TO create_VB the_DT PBS_NP flanked_VBD by_IN SalI_NP sites_NNS and_CC a_DT unique_JJ MluI_NP site_NN used_VBD to_TO verify_VB insertion_NN :_: 5'-TCGACACGCGTGGGGGCTCGTCCGAGATCGGGAGACCCCG-3_NP '_POS and_CC 5'-TCGACGGGGGCTCCCGATCTCGGACGAGCCCCCACGCGTG-3_NP '_POS ._SENT The_DT dl587_JJ PBS_NP was_VBD inserted_VBN into_IN the_DT SalI_NP site_NN downstream_RB of_IN the_DT MNDU3_NP promoter_NN using_VBG the_DT following_VBG 5'-phosphorylated_JJ oligonucleotides_NNS which_WDT anneal_VBP to_TO create_VB the_DT PBS_NP flanked_VBD by_IN SalI_NP sites_NNS and_CC a_DT unique_JJ MluI_NP site_NN used_VBD to_TO verify_VB insertion_NN :_: 5'-TCGACACGCGTGGAGGTTCCACCGAGATTTGGAGACCCCG-3_NP '_POS and_CC 5'-TCGACGGGGTCTCCAAATCTCGGTGGAACCTCCACGCGTG-3_NP '_POS ._SENT SIN_NN lentiviral_NN vectors_NNS containing_VBG different_JJ internal_JJ promoters_NNS were_VBD constructed_VBN using_VBG pCCL-hCMV-eGFP_NN ._SENT The_DT human_JJ cytomegalovirus_NN (_( hCMV_NP )_) internal_JJ promoter_NN in_IN this_DT vector_NN was_VBD removed_VBN with_IN ClaI_NP and_CC BamHI_NP and_CC replaced_VBN with_IN the_DT human_JJ elongation_NN factor_NN 1a_NP (_( hEF-1a_NP )_) promoter_NN ,_, which_WDT was_VBD acquired_VBN from_IN pV4.1e-hF.IX_NN (_( kindly_RB provided_VBN by_IN Hiroyuki_NP Nakai_NP ,_, Stanford_NP University_NP ,_, Stanford_NP ,_, Calif._NP )_) by_IN PCR_NP with_IN Pfu_NP Turbo_NP polymerase_NN (_( Stratagene_NP ,_, La_NP Jolla_NP ,_, Calif._NP )_) using_VBG the_DT primers_NNS 5'-GAAGATCGATCGTGAGGCTCCGGTG-3_NN '_'' and_CC 5'-GGTAGGATCCACGACACCTGAAATG-3_NP '_POS ,_, followed_VBN by_IN digestion_NN with_IN ClaI_NP and_CC BamHI_NP ._SENT To_TO replace_VB the_DT hCMV_NN promoter_NN in_IN pCCL-hCMV-eGFP_NN with_IN the_DT human_JJ ubiquitin_NN C_NP (_( hUbiqC_NN )_) promoter_NN ,_, the_DT plasmid_NN was_VBD first_RB digested_VBN with_IN ClaI_NP ,_, blunt_JJ ended_VBD with_IN Pfu_NP Turbo_NP polymerase_NN ,_, and_CC then_RB digested_VBN with_IN BamHI_NP ._SENT The_DT hUbiqC_NN promoter_NN fragment_NN was_VBD prepared_VBN from_IN pFUGW_NNS (_( kindly_RB provided_VBN by_IN Carlos_NP Lois_NP ,_, California_NP Institute_NP of_IN Technology_NP ,_, Pasadena_NP ,_, Calif._NP )_) by_IN digesting_VBG with_IN PacI_NP ,_, then_RB blunt_VB ending_VBG with_IN T4_NP polymerase_NN (_( Invitrogen_NP ,_, Carlsbad_NP ,_, Calif._NP )_) ,_, followed_VBN by_IN digestion_NN with_IN BamHI_NP ._SENT To_TO replace_VB the_DT hCMV_NN promoter_NN in_IN pCCL-hCMV-eGFP_NN with_IN the_DT mouse_NN phosphoglycerate_NN kinase_NN (_( mPGK_NN )_) promoter_NN ,_, the_DT hCMV_NP promoter_NN was_VBD removed_VBN by_IN digestion_NN with_IN ClaI_NP and_CC AgeI_NP ,_, and_CC an_DT oligonucleotide_NN containing_VBG restriction_NN sites_NNS ClaI-EcoRV-BamHI-AgeI_NP was_VBD inserted_VBN ._SENT The_DT mPGK_NN promoter_NN was_VBD excised_VBN from_IN pic20H-mPGK_NN with_IN HincII_NP and_CC BglII_NP and_CC inserted_VBN into_IN EcoR5_NP and_CC BamHI_NP ._SENT To_TO replace_VB the_DT hCMV_NN promoter_NN in_IN pCCL-hCMV-eGFP_NN with_IN the_DT SV40_NP promoter_NN ,_, the_DT hCMV-eGFP_NN cassette_NN was_VBD removed_VBN by_IN digestion_NN with_IN ClaI_NP and_CC SalI_NP and_CC an_DT oligonucleotide_NN containing_VBG restriction_NN sites_NNS ClaI-XhoI-EcoRV-BamHI-SmaI-SalI_NP was_VBD inserted_VBN ._SENT An_DT eGFP_NN fragment_NN was_VBD excised_VBN from_IN pMND-eGFP-SN_NN with_IN BamHI_NP and_CC inserted_VBN into_IN this_DT multicloning_NN site_NN ._SENT The_DT SV40_NP promoter_NN was_VBD excised_VBN from_IN pL-X-SN_NN with_IN XhoI_NP and_CC StuI_NP and_CC inserted_VBN into_IN this_DT multicloning_JJ site_NN after_IN digestion_NN with_IN XhoI_NP and_CC EcoRV_NP ._SENT The_DT MLV_NP PBS_NP was_VBD inserted_VBN into_IN a_DT BamHI_NP site_NN downstream_RB of_IN the_DT hEF-1a_NN and_CC hUbiqC_NN promoters_NNS and_CC upstream_RB of_IN the_DT mPGK_NN promoter_NN using_VBG 5'-phosphorylated_JJ oligonucleotides_NNS that_WDT anneal_VBP to_TO create_VB the_DT PBS_NP flanked_VBD by_IN BamHI_NP sites_NNS and_CC a_DT unique_JJ NheI_NP site_NN used_VBD to_TO verify_VB insertion_NN :_: 5'-GATCCGCTAGCGGGGGCTCGTCCGGGATCGGGAGACG-3_NP '_POS and_CC 5'-GATCCGTCTCCCGATCCCGGACGAGCCCCCGCTAGCG-3_NP '_POS ._SENT The_DT MLV_NP PBS_NP was_VBD inserted_VBN into_IN an_DT XhoI_NP site_NN upstream_RB of_IN the_DT SV40_NP promoter_NN using_VBG 5'-phosphorylated_JJ oligonucleotides_NNS that_WDT anneal_VBP to_TO create_VB the_DT PBS_NP flanked_VBD by_IN XhoI_NP sites_NNS and_CC a_DT unique_JJ NheI_NP site_NN used_VBD to_TO verify_VB insertion_NN :_: 5'-TCGAGGCTAGCGGGGGCTCGTCCGGGATCGGGAGAC-3_NP '_POS and_CC 5'-TCGAGTCTCCCGATCCCGGACGAGCCCCCGCTAGCC-3_NP '_POS ._SENT The_DT MLV_NP PBS_NP was_VBD inserted_VBN into_IN an_DT AgeI_NP site_NN downstream_RB of_IN the_DT SV40_NP promoter_NN using_VBG 5'-phosphorylated_JJ oligonucleotides_NNS that_WDT anneal_VBP to_TO create_VB the_DT PBS_NP flanked_VBD by_IN AgeI_NP sites_NNS and_CC a_DT unique_JJ NheI_NP site_NN used_VBD to_TO verify_VB insertion_NN :_: 5'-CCGGTGCTAGCGGGGGCTCGTCCGGGATCGGGAGAA-3_NP '_POS and_CC 5'-CCGGTTCTCCCGATCCCGGACGAGCCCCCGCTAGCA-3_NP '_POS ._SENT Vector_NP supernatant_JJ production_NN ._SENT |_SYM MLV_NP vector_NN supernatants_NNS were_VBD generated_VBN by_IN a_DT stably_RB transduced_JJ GP+E-86_NP packaging_NN cell_NN line_NN ._SENT Cells_NNS were_VBD plated_VBN close_RB to_TO confluency_NN in_IN T75_NP flasks_NNS ,_, grown_VBN at_IN 37C_JJ for_IN 48_CD h_NN in_IN 10_CD ml_NN of_IN DMEM_NP supplemented_VBD with_IN 10_CD %_NN FBS_NP ,_, 100_CD U_NN of_IN penicillin/ml_NN ,_, 100_CD mug_NN of_IN streptomycin/ml_NN ,_, 2_CD mM_NP l-glutamine_NN ._SENT Vector_NN supernatants_NNS were_VBD filtered_VBN through_IN a_DT 0.45-mum_NN filter_NN and_CC frozen_VBN at_IN -80C_NN until_IN used_VBN ._SENT Vesicular_JJ stomatitis_NN virus_NN glycoprotein-pseudotyped_JJ lentiviral_JJ vector_NN supernatants_NNS were_VBD generated_VBN by_IN transient_JJ transfection_NN of_IN 293T_JJ cells_NNS (_( ATCC_NP CRL-1268_NP )_) as_IN previously_RB described_VBN using_VBG 10_CD mug_NN of_IN vector_NN plasmid_NN ,_, 10_CD mug_NN of_IN pRDelta8.9_JJ packaging_NN plasmid_NN ,_, and_CC 2_CD mug_NN of_IN pMD.G(VSV)_JJ envelope_NN plasmid_NN ._SENT Twelve_CD hours_NNS after_IN transfection_NN ,_, cells_NNS were_VBD treated_VBN with_IN 10_CD mM_NP sodium_NN butyrate_NN (_( Sigma_NP Scientific_NP ,_, Inc._NP ,_, Brighton_NP ,_, Mich._NP )_) for_IN 12_CD h_NN as_IN previously_RB described_VBN ._SENT After_IN 12_CD h_NN of_IN exposure_NN to_TO sodium_NN butyrate_NN ,_, the_DT cells_NNS were_VBD washed_VBN twice_RB with_IN phosphate-buffered_JJ saline_JJ and_CC refed_JJ with_IN fresh_JJ medium_NN ._SENT Thereafter_RB ,_, supernatants_NNS were_VBD collected_VBN every_DT 12_CD h_NN for_IN 3_CD to_TO 5_CD days_NNS ,_, filtered_VBN through_IN a_DT 0.2-mum_NN filter_NN flask_NN (_( Nalgene_NP ,_, Rochester_NP ,_, N.Y._NP )_) ,_, and_CC concentrated_VBD by_IN ultracentrifugation_NN at_IN 50,000_CD x_NN g_NN for_IN 140_CD min_NN as_IN previously_RB described_VBN ._SENT Pellets_NNS were_VBD resuspended_VBN in_IN serum-free_JJ DMEM_NP and_CC stored_VBN at_IN -80C_NN until_IN used_VBN ._SENT Vector_NP supernatant_JJ titer_NN determination_NN ._SENT |_SYM Vector_NP supernatant_JJ titers_NNS were_VBD determined_VBN by_IN endpoint_NN dilution_NN ._SENT 293_CD cells_NNS (_( ATCC_NP CRL-1573_NP )_) were_VBD seeded_VBN at_IN 105_CD cells/well_NN in_IN six-well_NN cell_NN culture_NN plates_NNS (_( Corning_NP Inc._NP ,_, Miami_NP ,_, Fla._NP )_) in_IN DMEM_NP supplemented_VBD with_IN 10_CD %_NN FBS_NP ,_, 100_CD U_NN of_IN penicillin/ml_NN ,_, 100_CD mug_NN of_IN streptomycin/ml_NN ,_, 2_CD mM_NP l-glutamine_NN and_CC placed_VBN in_IN a_DT 37C_JJ incubator_NN for_IN 12_CD h._NP Cells_NP were_VBD then_RB transduced_VBN with_IN 1-ml_JJ serial_JJ dilutions_NNS (_( i.e._FW ,_, 10-1_CD ,_, 10-2_CD ,_, 10-3_CD )_) of_IN vector_NN supernatant_JJ and_CC analyzed_VBN by_IN flow_NN cytometry_NN for_IN eGFP_NN expression_NN 48_CD h_NN later_RBR ._SENT Titers_NNS were_VBD calculated_VBN by_IN multiplying_VBG the_DT number_NN of_IN cells_NNS at_IN the_DT time_NN of_IN vector_NN supernatant_JJ addition_NN by_IN the_DT percentage_NN of_IN eGFP-positive_JJ cells_NNS determined_VBN by_IN flow_NN cytometry_NN divided_VBN by_IN 100_CD ,_, multiplied_VBN by_IN the_DT dilution_NN factor_NN to_TO yield_VB the_DT number_NN of_IN infectious_JJ units_NNS (_( IU_NP )_) per_IN milliliter_NN ._SENT Titers_NNS ranged_VBD between_IN 0.5_CD x_NN 106_CD and_CC 10_CD x_SYM 106_CD IU/ml_NN before_IN ultracentrifugation_NN and_CC 0.5_CD x_SYM 108_CD and_CC 5_CD x_SYM 108_CD IU/ml_NN after_IN ultracentrifugation_NN ._SENT Lentiviral_JJ vector_NN transductions_NNS ._SENT |_SYM Target_NP cells_NNS that_WDT were_VBD transduced_VBN to_TO determine_VB whether_IN they_PP possessed_VBD RBS-mediated_JJ repressive_JJ activity_NN were_VBD transduced_VBN in_IN parallel_NN and_CC under_IN the_DT same_JJ conditions_NNS as_IN F9_NP EC_NP and_CC 293_CD cells_NNS in_IN order_NN to_TO control_VB for_IN small_JJ differences_NNS in_IN vector_NN titer_NN that_WDT could_MD contribute_VB to_TO differences_NNS in_IN transduction_NN efficiency_NN ._SENT Most_JJS cell_NN types_NNS were_VBD transduced_VBN for_IN 12_CD h_NN using_VBG a_DT final_JJ vector_NN concentration_NN of_IN 1_CD x_NN 106_CD to_TO 2_CD x_SYM 106_CD IU/ml_NN and_CC a_DT multiplicity_NN of_IN infection_NN of_IN 5_CD to_TO 10_CD in_IN their_PP$ normal_JJ growth_NN medium_NN ._SENT CD34+_NP ,_, CD34+_NP CD38-_NP ,_, and_CC primary_JJ mouse_NN BM_NP cells_NNS required_VBD higher_JJR concentrations_NNS of_IN vector_NN for_IN efficient_JJ transduction_NN and_CC were_VBD transduced_VBN with_IN a_DT final_JJ vector_NN concentration_NN of_IN 5_CD x_NN 107_CD to_TO 10_CD x_SYM 107_CD IU/ml_NP plus_CC Polybrene_NP at_IN 8_CD mug/ml_NN ._SENT After_IN transduction_NN ,_, cells_NNS were_VBD passaged_VBN in_IN culture_NN for_IN 6_CD to_TO 10_CD days_NNS and_CC then_RB analyzed_VBD by_IN flow_NN cytometry_NN for_IN eGFP_NN expression_NN ._SENT PCR_NP for_IN relative_JJ copy_NN number_NN ._SENT |_SYM Genomic_NP DNA_NP was_VBD isolated_VBN using_VBG a_DT DNeasy_NP tissue_NN kit_NN (_( Qiagen_NP ,_, Valencia_NP ,_, Calif._NP )_) for_IN use_NN as_IN template_NN in_IN a_DT semiquantitative_JJ PCR_NP to_TO determine_VB the_DT relative_JJ vector_NN copy_NN number_NN in_IN transduced_JJ cells_NNS ._SENT To_TO generate_VB the_DT standard_JJ curve_NN ,_, we_PP used_VBD a_DT GP+E-86_NP cell_NN clone_NN containing_VBG five_CD copies_NNS of_IN the_DT MND-eGFP-SN_NP vector_NN ,_, as_RB previously_RB described_VBN ._SENT The_DT standard_JJ curve_NN was_VBD generated_VBN using_VBG dilutions_NNS representing_VBG 4_CD ,_, 2_CD ,_, 1_CD ,_, 0.5_CD ,_, 0.25_CD ,_, 0.13_CD ,_, 0.06_CD ,_, and_CC 0.03_CD copies/cell_NNS ._SENT DNA_NN of_IN the_DT five-copy_JJ clone_NN was_VBD mixed_VBN with_IN DNA_NN of_IN nontransduced_JJ GP+E-86_NP cells_NNS ,_, so_RB that_IN the_DT total_JJ input_NN template_NN DNA_NN was_VBD maintained_VBN constant_JJ ._SENT Template_NN DNA_NN was_VBD diluted_VBN to_TO 100_CD ng_NNS in_IN 44_CD mul_NN of_IN double-distilled_JJ (_( ddH2O_NN )_) in_IN a_DT PCR_NP tube_NN ._SENT Three_CD microliters_NNS of_IN this_DT solution_NN ,_, containing_VBG 7_CD ng_NNS of_IN template_NN DNA_NN ,_, was_VBD removed_VBN and_CC placed_VBN into_IN a_DT second_JJ tube_NN ,_, leaving_VBG 41_CD mul_NN containing_VBG 93_CD ng_NNS of_IN template_NN DNA_NN in_IN the_DT first_JJ tube_NN ._SENT Master_NN mix_NN solutions_NNS were_VBD then_RB added_VBN to_TO make_VB a_DT final_JJ volume_NN of_IN 50_CD mul_NN containing_VBG 2.5_CD U_NN of_IN Pfu_NP Turbo_NP polymerase_NN ,_, 1x_NP Pfu_NP PCR_NP buffer_NN (_( Stratagene_NP )_) ,_, each_DT primer_NN at_IN a_DT 0.2_CD muM_NN concentration_NN ,_, and_CC each_DT deoxynucleoside_NN triphosphate_NN at_IN a_DT 0.2_CD mM_NP concentration_NN ._SENT The_DT tube_NN containing_VBG 93_CD ng_NNS of_IN template_NN DNA_NN was_VBD used_VBN for_IN eGFP_NP PCR_NP ,_, and_CC the_DT tube_NN containing_VBG 7_CD ng_NNS of_IN template_NN DNA_NN was_VBD used_VBN for_IN beta-actin_NP PCR_NP to_TO control_VB for_IN varying_VBG input_NN template_NN content_NN ._SENT eGFP_JJ primer_NN sequences_NNS used_VBN were_VBD sense_NN ,_, 5'-ATGGTGAGCAAGGGCGAGGAGCTG-3_NP '_POS ,_, and_CC antisense_NN ,_, 5'-GCCGTCGTCCTTGAAGAAGATGGTG-3_NP '_POS ,_, yielding_VBG a_DT product_NN of_IN 314_CD bp_NN ._SENT beta-Actin_NN primer_NN sequences_NNS used_VBN were_VBD sense_NN ,_, 5'-GTACCACAGGCATTGTGATG-3_NP '_POS ,_, and_CC antisense_NN ,_, 5'-GCAACATAGCACAGCTTCTC-3_NP '_POS ,_, yielding_VBG a_DT product_NN of_IN 219_CD bp_NN ,_, as_RB previously_RB described_VBN ._SENT Reactions_NNS were_VBD performed_VBN on_IN a_DT Perkin-Elmer_NP GeneAmp_NP 9600_CD PCR_NP system_NN ._SENT Both_CC the_DT eGFP_NN and_CC beta-actin_NN PCRs_NNS were_VBD conducted_VBN for_IN 28_CD cycles_NNS with_IN denaturation_NN at_IN 94C_NN for_IN 30_CD s_NNS ,_, annealing_VBG at_IN 65C_JJ for_IN 1_CD min_NN ,_, and_CC extension_NN at_IN 72C_NP for_IN 1_CD min_NN ._SENT Reaction_NN products_NNS were_VBD separated_VBN by_IN electrophoresis_NN on_IN 0.8_CD %_NN agarose-EtBr_NN gels_NNS and_CC visualized_VBD using_VBG an_DT Eagle_NP Eye_NP charge-coupled_JJ device_NN camera_NN (_( Stratagene_NP )_) ._SENT Nuclear_NP extracts_VBZ and_CC EMSAs_NP ._SENT |_SYM Nuclear_NP extracts_VBZ were_VBD prepared_VBN essentially_RB as_RB described_VBN elsewhere_RB ._SENT Nuclear_NP extracts_VBZ were_VBD prepared_VBN without_IN dialysis_NN against_IN modified_JJ Dignam_NP buffer_NN D_NP and_CC were_VBD left_VBN in_IN Dignam_NP buffer_NN C_NP (_( 20_CD mM_NP HEPES_NP [_SYM pH_NN 7.9_CD ]_SYM ,_, 25_CD %_NN [_SYM vol/vol_NN ]_SYM glycerol_NN ,_, 0.3_CD M_NP NaCl_NP ,_, 1.5_CD mM_NP MgCl2_NP ,_, 0.2_CD mM_NP EDTA_NP ,_, 0.5_CD mM_NP phenylmethylsulfonyl_NN fluoride_NN ,_, 0.5_CD mM_NP dithiothreitol_NN )_) as_IN previously_RB described_VBN ._SENT EMSAs_NNS were_VBD performed_VBN using_VBG previously_RB described_VBN binding_JJ conditions_NNS ._SENT Probes_NNS were_VBD prepared_VBN by_IN annealing_VBG complementary_JJ single-stranded_JJ oligonucleotides_NNS and_CC then_RB end_VB labeling_VBG with_IN [_SYM gamma-32P]ATP_NN (_( Amersham_NP Biosciences_NP )_) using_VBG T4_NP polynucleotide_NN kinase_NN (_( Invitrogen_NP )_) ._SENT Extended_VBN 28-bp_JJ PBS_NP probes_NNS were_VBD used_VBN due_RB to_TO reported_JJ increased_VBN binding_NN in_IN EMSA_NP compared_VBN to_TO the_DT 18-bp_JJ core_NN PBS_NP sequence_NN (_( underlined_VBN below_IN )_) ._SENT Oligonucleotide_NN probes_NNS were_VBD as_RB follows_VBZ :_: MLV_NP PBS_NP ,_, 5'-GGGGGCTCGTCCGGGATCGGGAGACCCC-3_JJ '_'' ;_: B2_JJ PBS_NP ,_, 5'-GGGGGCTCGTCCGAGATCGGGAGACCCC-3_JJ '_'' ;_: dl587_JJ PBS_NP ,_, 5'-GGAGGTTCCACCGAGATTTGGAGACCCC-3_NP '_POS (_( only_RB one_CD strand_NN for_IN each_DT is_VBZ shown_VBN )_) ._SENT Radioactively_RB labeled_VBN double-stranded_JJ DNA_NN oligonucleotides_NNS were_VBD purified_VBN using_VBG G-25_NP columns_NNS (_( Amersham_NP Biosciences_NP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._SENT Radioactive_JJ labeling_VBG ranged_VBD from_IN 200,000_CD to_TO 400,000_CD cpm/ng_NN ._SENT Each_DT binding_JJ reaction_NN was_VBD performed_VBN with_IN 5_CD to_TO 15_CD mul_NN of_IN nuclear_JJ extract_NN in_IN a_DT total_JJ volume_NN of_IN 30_CD mul_NN of_IN Thornell_NP binding_JJ buffer_NN (_( 25_CD mM_NP HEPES_NP [_SYM pH_NN 7.9_CD ]_SYM ,_, 1_CD mM_NP EDTA_NP ,_, 10_CD %_NN [_SYM vol/vol_NN ]_SYM glycerol_NN ,_, 5_CD mM_NP dithiothreitol_NN ,_, 0.5_CD mM_NP phenylmethylsulfonyl_NN fluoride_NN )_) containing_VBG 25_CD ng_NNS of_IN poly(dI-dC)/ml_NN ,_, 5_CD mM_NP NaCl_NP ,_, 5_CD mM_NP KCl_NP ,_, 3_CD mM_NP MgCl2_NP ,_, and_CC 0.1_CD mM_NP ZnCl2_NP ,_, as_RB previously_RB described_VBN ._SENT Prior_RB to_TO the_DT addition_NN of_IN probe_NN ,_, binding_VBG reaction_NN mixtures_NNS were_VBD preincubated_VBN at_IN 30C_JJ for_IN 20_CD min_NN ,_, and_CC then_RB 0.5_CD ng_NNS of_IN double-stranded_JJ radioactively_RB labeled_VBN probe_NN was_VBD added_VBN in_IN a_DT 1-mul_NP volume_NN and_CC reactions_NNS were_VBD incubated_VBN for_IN an_DT additional_JJ 20_CD min_NN at_IN 30C_JJ ._SENT Binding_JJ reactions_NNS were_VBD run_VBN on_IN a_DT 6_CD %_NN native_JJ acrylamide_NN gel_NN ._SENT The_DT gel_NN was_VBD loaded_VBN at_IN room_NN temperature_NN ,_, run_VBN for_IN 20_CD min_NN at_IN 130_CD V_CD ,_, and_CC then_RB transferred_VBN to_TO 4C_JJ and_CC run_VBN at_IN 175_CD V_CD for_IN approximately_RB 4_CD h_NN in_IN Tris-glycine_NP buffer_NN (_( 5_CD mM_NP Tris_NP [_SYM pH_NN 8.5_CD ]_SYM ,_, 38_CD mM_NP glycine_NN ,_, 0.2_CD mM_NP EDTA_NP )_) ._SENT After_IN electrophoresis_NN ,_, gels_NNS were_VBD dried_VBN and_CC opposed_VBN to_TO film_NN for_IN 1_CD to_TO 4_CD days_NNS at_IN -80C_NN with_IN intensifying_VBG screens_NNS ._SENT Mouse_NN bone_NN marrow_NN harvest_NN ,_, transduction_NN ,_, and_CC transplantation_NN ._SENT |_SYM Mice_NN were_VBD purchased_VBN from_IN Jackson_NP Laboratories_NPS (_( Bar_NP Harbor_NP ,_, Maine_NP )_) and_CC maintained_VBN at_IN the_DT Childrens_NP Hospital_NP Los_NP Angeles_NP Central_NP Animal_NP Facility_NP ._SENT All_DT studies_NNS were_VBD approved_VBN by_IN the_DT Institutional_NP Animal_NP Care_NP and_CC Use_NP Committee_NP at_IN Childrens_NP Hospital_NP Los_NP Angeles_NP ._SENT Donor_NN marrow_NN was_VBD harvested_VBN from_IN 8-_CD to_TO 12-week-old_JJ male_JJ B6/SJL_NP mice_NNS 2_CD days_NNS after_IN 5-fluorouracil_NN intravenous_JJ injection_NN (_( 150_CD mg/kg_NN of_IN body_NN weight_NN ;_: American_NP Pharmaceutical_NP Partners_NP ,_, Los_NP Angeles_NP ,_, Calif._NP )_) ._SENT The_DT marrow_NN was_VBD cultured_VBN at_IN a_DT density_NN of_IN 2_CD x_SYM 106_CD cells/ml_NN in_IN IMDM_NP supplemented_VBD with_IN 20_CD %_NN FBS_NP ,_, 10_CD ng_NNS of_IN murine_JJ IL-3_NP (_( Biosource_NP International)/ml_NP ,_, 2.5_CD ng_NNS of_IN murine_JJ stem_NN cell_NN factor_NN (_( Biosource_NP International)/ml_NP ,_, 50_CD ng_NNS of_IN human_JJ IL-6_NP (_( Biosource_NP International)/ml_NP ,_, 2_CD mM_NP l-glutamine_NN ,_, 100_CD U_NN of_IN penicillin/ml_NN ,_, 100_CD mug_NN of_IN streptomycin/ml_NN ,_, and_CC 0.01_CD mM_NNS 2-mercaptoethanol_JJ ._SENT Harvested_VBN cells_NNS were_VBD prestimulated_VBN in_IN cytokine-containing_JJ medium_NN for_IN 12_CD h_NN prior_JJ to_TO transduction_NN ._SENT Lentiviral_JJ supernatant_JJ was_VBD added_VBN to_TO a_DT final_JJ concentration_NN of_IN 2_CD x_SYM 107_CD IU/ml_NN ._SENT Polybrene_NP was_VBD added_VBN to_TO a_DT final_JJ concentration_NN of_IN 6_CD mug/ml_NN ._SENT Recipient_NN 8-_CD to_TO 12-week-old_JJ female_JJ C57Bl/6_NP mice_NNS were_VBD exposed_VBN to_TO two_CD doses_NNS of_IN 600_CD cGy_NN of_IN gamma_NN irradiation_NN (_( 128_CD cGy/min_NN from_IN a_DT cesium-137_JJ source_NN )_) on_IN two_CD consecutive_JJ days_NNS (_( total_JJ of_IN 1,200_CD cGy_NN )_) ._SENT One_CD to_TO two_CD hours_NNS following_VBG the_DT second_JJ dose_NN of_IN radiation_NN ,_, 2_CD x_SYM 106_CD to_TO 4_CD x_SYM 106_CD transduced_JJ donor_NN BM_NN cells_NNS were_VBD injected_VBN into_IN the_DT tail_JJ vein_NN of_IN each_DT recipient_NN in_IN 200_CD mul_NN of_IN phosphate-buffered_JJ saline_NN containing_VBG 50_CD U_NN of_IN heparin/ml_NN ._SENT Antibiotics_NNS were_VBD added_VBN to_TO the_DT drinking_NN water_NN for_IN 3_CD weeks_NNS posttransplantation_NN (_( 200_CD mug_NN of_IN Maxim-200/ml_NP ;_: Phoenix_NP Pharmaceuticals_NPS ,_, St._NP Joseph_NP ,_, Mo._NP )_) ._SENT The_DT donor-recipient_JJ pairs_NNS were_VBD congenic_JJ at_IN the_DT CD45_NP locus_NN ,_, with_IN donors_NNS expressing_VBG CD45.1_NP and_CC recipients_NNS expressing_VBG CD45.2_JJ isoforms_NNS of_IN CD45_NP ,_, which_WDT are_VBP easily_RB distinguishable_JJ by_IN flow_NN cytometry_NN using_VBG commercially_RB available_JJ antibodies_NNS (_( BD_NP Biosciences_NP ,_, Palo_NP Alto_NP ,_, Calif._NP )_) ._SENT Modifications_NNS made_VBD to_TO the_DT MLV_NP vector_NN increase_VB its_PP$ frequency_NN of_IN expression_NN in_IN F9_NP EC_NP cells_NNS ._SENT |_SYM We_PP made_VBD a_DT series_NN of_IN retroviral_JJ vectors_NNS containing_VBG from_IN one_CD to_TO three_CD modifications_NNS to_TO the_DT MLV_NP vector_NN to_TO remove_VB cis-acting_NN elements_NNS reported_VBD to_TO restrict_VB expression_NN of_IN MLV_NP in_IN F9_NP EC_NP cells_NNS ._SENT Figure_NN shows_VBZ the_DT arrangement_NN of_IN elements_NNS contained_VBN in_IN the_DT full-length_JJ MLV_NP vector_NN constructs_NNS (_( not_RB drawn_VBN to_TO scale_VB )_) ._SENT The_DT vector_NN expresses_VBZ eGFP_NN from_IN the_DT 5'LTR_NN and_CC neomycin_NN resistance_NN (_( Neor_NP )_) from_IN an_DT internal_JJ SV40_NP promoter_NN ._SENT Figure_NN shows_VBZ the_DT contribution_NN each_DT of_IN the_DT three_CD modifications_NNS ,_, both_CC alone_RB and_CC in_IN combination_NN ,_, made_VBN to_TO the_DT frequency_NN of_IN expression_NN in_IN F9_NP EC_NP cells_NNS ._SENT To_TO control_VB for_IN differences_NNS in_IN titer_NN between_IN vector_NN supernatants_NNS ,_, 3T3_JJ cells_NNS ,_, which_WDT are_VBP permissive_JJ for_IN MLV_NP expression_NN ,_, were_VBD transduced_VBN in_IN parallel_NN and_CC under_IN the_DT same_JJ conditions_NNS as_IN F9_NP EC_NP cells_NNS ._SENT Values_NNS are_VBP expressed_VBN as_IN the_DT percentage_NN of_IN eGFP-positive_JJ F9_NP EC_NP cells_NNS relative_JJ to_TO the_DT percentage_NN of_IN eGFP-positive_JJ 3T3_JJ cells_NNS 7_CD days_NNS after_IN transduction_NN ._SENT Figure_NN shows_VBZ that_IN the_DT unmodified_JJ MLV_NP vector_NN ,_, L_NP ,_, expresses_VBZ rarely_RB in_IN F9_NP EC_NP cells_NNS ._SENT Replacing_VBG the_DT MLV_NP PBS_NP with_IN the_DT dl587_JJ PBS_NP in_IN vector_NN LD_NN ,_, thereby_RB removing_VBG the_DT RBS_NN ,_, alleviates_VBZ repression_NN in_IN a_DT substantial_JJ fraction_NN of_IN F9_NP EC_NP cells_NNS ._SENT Replacing_VBG the_DT MLV_NP U3_NP with_IN the_DT MPSV_NP U3_NP alone_RB in_IN vector_NN M_NN ,_, while_IN leaving_VBG the_DT MLV_NP PBS_NP and_CC therefore_RB the_DT RBS_NN in_IN place_NN ,_, alleviates_VBZ very_RB little_JJ repression_NN in_IN F9_NP EC_NP cells_NNS ._SENT MPSV_NP is_VBZ a_DT variant_NN of_IN the_DT Moloney_NP sarcoma_NN virus_NN that_WDT had_VBD greater_JJR expression_NN in_IN myeloid_JJ cells_NNS ,_, and_CC the_DT MPSV_NP LTR_NP was_VBD isolated_VBN and_CC shown_VBN to_TO express_VB better_JJR than_IN the_DT MLV_NP LTR_NP in_IN EC_NP cells_NNS ._SENT Among_IN the_DT seven_CD single-base_JJ differences_NNS between_IN the_DT MLV_NP and_CC the_DT MPSV_NP enhancer_NN repeats_NNS ,_, one_CD of_IN these_DT single-base_JJ differences_NNS has_VBZ been_VBN shown_VBN to_TO introduce_VB a_DT functional_JJ Sp1_NP transcription_NN factor_NN binding_VBG site_NN in_IN the_DT MPSV_NP enhancer_NN repeat_NN that_WDT is_VBZ not_RB present_JJ in_IN the_DT MLV_NP enhancer_NN repeat_NN ._SENT This_DT Sp1_NP site_NN accounts_NNS for_IN much_JJ of_IN the_DT increase_NN in_IN activity_NN of_IN this_DT enhancer_NN in_IN F9_NP EC_NP cells_NNS ._SENT Replacing_VBG the_DT MLV_NP U3_NP with_IN the_DT MPSV_NP U3_NP and_CC replacing_VBG the_DT MLV_NP PBS_NP with_IN the_DT dl587_JJ PBS_NP in_IN combination_NN in_IN vector_NN MD_NNS ,_, thereby_RB removing_VBG the_DT RBS_NN ,_, alleviates_VBZ repression_NN in_IN a_DT substantial_JJ fraction_NN of_IN F9_NP EC_NP ._SENT Removing_VBG the_DT NCR_NP from_IN the_DT U3_NP of_IN MD_NP to_TO make_VB the_DT triply_RB modified_VBN vector_NN MND_NP further_RBR alleviates_VBZ repression_NN in_IN F9_NP EC_NP cells_NNS ._SENT In_IN each_DT case_NN where_WRB the_DT MLV_NP PBS_NP ,_, and_CC therefore_RB the_DT RBS_NN ,_, is_VBZ present_JJ expression_NN is_VBZ nearly_RB completely_RB repressed_VBN ._SENT Figure_NN shows_VBZ the_DT contribution_NN that_IN each_DT of_IN these_DT three_CD modifications_NNS made_VBN to_TO expression_NN in_IN F9_NP EC_NP cells_NNS after_IN selection_NN in_IN G418_NP for_IN expression_NN of_IN Neor_NP from_IN a_DT downstream_JJ internal_JJ SV40_NP promoter_NN ._SENT Each_DT of_IN these_DT F9_NP EC_NP pools_NNS was_VBD selected_VBN with_IN 0.75_CD mug_NN of_IN G418/ml_NP for_IN 10_CD days_NNS from_IN a_DT pool_NN of_IN cells_NNS that_WDT was_VBD transduced_VBN with_IN a_DT dilution_NN of_IN vector_NN supernatant_JJ that_IN transduced_JJ 3T3_JJ cells_NNS in_IN parallel_NN to_TO <10_JJ %_NN eGFP_NN positivity_NN ,_, so_RB that_IN most_JJS cells_NNS within_IN these_DT pools_NNS should_MD contain_VB only_RB a_DT single_JJ copy_NN of_IN the_DT vector_NN ._SENT In_IN 0.75_CD mug_NN of_IN G418/ml_NP ,_, all_DT nontransduced_JJ F9_NP EC_NP cells_NNS in_IN control_NN wells_NNS were_VBD dead_JJ within_IN 7_CD days_NNS ._SENT Following_VBG G418_NP selection_NN ,_, the_DT cells_NNS were_VBD passaged_VBN in_IN culture_NN for_IN an_DT additional_JJ 2_CD weeks_NNS before_IN analysis_NN of_IN eGFP_NN expression_NN by_IN flow_NN cytometry_NN ._SENT Figure_NN demonstrates_VBZ the_DT same_JJ pattern_NN of_IN increased_VBN expression_NN of_IN eGFP_NN from_IN the_DT modified_VBN vectors_NNS as_IN in_IN unselected_JJ F9_NP EC_NP cells_NNS ._SENT Again_RB ,_, in_IN each_DT case_NN ,_, removing_VBG the_DT RBS_NN by_IN replacing_VBG the_DT MLV_NP PBS_NP with_IN the_DT dl587_JJ PBS_NP made_VBD the_DT largest_JJS contribution_NN to_TO increased_VBN expression_NN ,_, while_IN changing_VBG the_DT enhancer_NN or_CC deleting_VBG the_DT NCR_NP made_VBD only_RB more_RBR modest_JJ improvements_NNS ._SENT Vectors_NNS containing_VBG the_DT MLV_NP PBS_NP ,_, and_CC therefore_RB the_DT RBS_NP (_( L_NP and_CC M_NP )_) ,_, expressed_VBN in_IN less_JJR than_IN 5_CD %_NN of_IN the_DT G418-selected_NP F9_NP cells_NNS ,_, whereas_IN the_DT vectors_NNS lacking_VBG the_DT RBS_NP (_( LD_NP ,_, MD_NP ,_, and_CC MND_NP )_) expressed_VBD in_IN 80_CD to_TO 90_CD %_NN of_IN selected_JJ cells_NNS ._SENT The_DT RBS_JJ repressed_JJ expression_NN from_IN an_DT internal_JJ MNDU3_NP promoter_NN in_IN a_DT SIN_JJ lentiviral_JJ vector_NN ._SENT |_SYM To_TO determine_VB if_IN the_DT RBS_NN was_VBD capable_JJ of_IN repressing_VBG expression_NN outside_IN of_IN its_PP$ normal_JJ retroviral_JJ genome_NN context_NN ,_, a_DT series_NN of_IN SIN_JJ lentiviral_JJ vectors_NNS were_VBD constructed_VBD having_VBG an_DT internal_JJ MNDU3_NP promoter_NN driving_VBG eGFP_NN expression_NN with_IN one_CD of_IN the_DT three_CD PBS_NP sequences_NNS under_IN investigation_NN inserted_VBN between_IN the_DT promoter_NN and_CC the_DT eGFP_NN transgene_NN ._SENT SIN_NN lentiviral_NN vectors_NNS do_VBP not_RB efficiently_RB express_JJ transcript_NN from_IN their_PP$ own_JJ LTR_NN after_IN reverse_JJ transcription_NN ,_, and_CC thus_RB eGFP_JJ expression_NN reflects_VBZ the_DT activity_NN of_IN the_DT internal_JJ promoter_NN ._SENT Each_DT vector_NN supernatant_JJ in_IN this_DT series_NN was_VBD produced_VBN and_CC the_DT titer_NN was_VBD determined_VBN simultaneously_RB on_IN 293_CD cells_NNS ._SENT Based_VBN on_IN these_DT titer_NN values_NNS ,_, F9_NP EC_NP and_CC 293_CD cells_NNS were_VBD transduced_VBN in_IN parallel_RB using_VBG identical_JJ conditions_NNS ._SENT After_IN 6_CD to_TO 10_CD days_NNS the_DT cells_NNS were_VBD harvested_VBN and_CC analyzed_VBN for_IN eGFP_NN expression_NN by_IN flow_NN cytometry_NN ._SENT Flow_NN cytometric_JJ analyses_NNS from_IN a_DT typical_JJ experiment_NN are_VBP shown_VBN in_IN Fig._NN ._SENT The_DT averages_NNS of_IN 15_CD experiments_NNS are_VBP plotted_VBN in_IN Fig._NN ._SENT In_IN 293_CD cells_NNS ,_, all_RB four_CD vectors_NNS were_VBD expressed_VBN at_IN the_DT same_JJ frequency_NN ._SENT In_IN contrast_NN ,_, the_DT lentiviral_JJ vector_NN containing_VBG the_DT MLV_NP PBS_NP shows_VBZ essentially_RB no_DT expression_NN in_IN the_DT F9_NP EC_NP cells_NNS ,_, whereas_IN the_DT other_JJ vectors_NNS ,_, with_IN no_DT PBS_NP or_CC with_IN the_DT B2_JJ or_CC dl587_JJ PBS_NP ,_, all_DT expressed_VBN at_IN similar_JJ frequencies_NNS ._SENT An_DT alternative_JJ explanation_NN for_IN the_DT results_NNS shown_VBN in_IN Fig._NN is_VBZ that_IN the_DT vector_NN containing_VBG the_DT MLV_NP PBS_NP was_VBD not_RB transferred_VBN or_CC integrated_VBN at_IN the_DT same_JJ frequency_NN as_IN the_DT other_JJ vectors_NNS in_IN the_DT series_NN ._SENT To_TO rule_VB out_RP this_DT possibility_NN ,_, we_PP performed_VBD semiquantitative_JJ PCR_NP on_IN genomic_JJ DNA_NN from_IN transduced_JJ 293_CD and_CC F9_NP EC_NP cells_NNS ._SENT Figure_NN shows_VBZ that_IN the_DT vector_NN containing_VBG the_DT MLV_NP PBS_NP was_VBD transferred_VBN at_IN a_DT similar_JJ relative_JJ frequency_NN as_IN the_DT vectors_NNS containing_VBG the_DT B2_JJ and_CC dl587_JJ PBS_NP and_CC the_DT vector_NN containing_VBG no_DT PBS_NP ._SENT Thus_RB ,_, the_DT difference_NN in_IN expression_NN by_IN the_DT vector_NN carrying_VBG the_DT MLV_NP PBS_NP is_VBZ not_RB due_JJ to_TO poor_JJ gene_NN transfer_NN and_CC therefore_RB reflects_VBZ repression_NN of_IN expression_NN ._SENT The_DT RBS_JJ repressed_JJ expression_NN from_IN internal_JJ SV40_NP ,_, hUbiqC_NP ,_, hEF-1alpha_NP ,_, and_CC mPGK_NN promoters_NNS ._SENT |_SYM Previous_JJ studies_NNS have_VBP demonstrated_VBN that_IN within_IN the_DT context_NN of_IN the_DT retroviral_JJ genome_NN ,_, the_DT RBS_NN was_VBD able_JJ to_TO repress_VB transcription_NN from_IN two_CD downstream_JJ internal_JJ heterologous_JJ viral_JJ promoters_NNS ,_, SV40_NP and_CC AdMLP_NP ._SENT To_TO determine_VB whether_IN the_DT RBS_NN also_RB repressed_VBN transcription_NN from_IN cellular_JJ promoters_NNS ,_, we_PP constructed_VBD SIN_JJ lentiviral_JJ vectors_NNS analogous_JJ to_TO the_DT vector_NN series_NN introduced_VBN in_IN Fig._NN ,_, but_CC having_VBG either_CC the_DT SV40_NP ,_, hUbiqC_NP ,_, mPGK_NN ,_, or_CC hEF-1a_NN promoter_NN driving_VBG eGFP_NN expression_NN ,_, with_IN and_CC without_IN the_DT MLV_NP PBS_NP sequence_NN inserted_VBD either_RB immediately_RB upstream_RB or_CC immediately_RB downstream_JJ of_IN the_DT promoter_NN ._SENT F9_NP EC_NP cells_NNS and_CC 293_CD cells_NNS were_VBD transduced_VBN in_IN parallel_NN with_IN the_DT various_JJ vector_NN constructs_NNS using_VBG identical_JJ conditions_NNS ._SENT Cells_NNS were_VBD passaged_VBN in_IN culture_NN for_IN 6_CD to_TO 10_CD days_NNS and_CC then_RB analyzed_VBD for_IN eGFP_NN expression_NN by_IN flow_NN cytometry_NN ._SENT Figure_NN shows_VBZ the_DT average_JJ results_NNS from_IN two_CD separate_JJ experiments_NNS ._SENT The_DT data_NNS are_VBP presented_VBN as_IN the_DT percentage_NN of_IN eGFP-positive_JJ F9_NP EC_NP cells_NNS normalized_VBD to_TO the_DT percentage_NN of_IN eGFP-positive_JJ 293_CD cells_NNS in_IN the_DT same_JJ vector_NN arm_NN ,_, relative_JJ to_TO the_DT F9_NP EC/293_NP transduction_NN ratio_NN achieved_VBN by_IN vector_NN with_IN no_DT MLV_NP PBS_NP multiplied_VBD by_IN 100_CD ._SENT Figure_NN shows_VBZ that_IN the_DT SV40_NP promoter_NN and_CC the_DT three_CD cellular_JJ promoters_NNS examined_VBN were_VBD substantially_RB repressed_VBN by_IN the_DT RBS_NN ,_, although_IN to_TO varying_VBG degrees_NNS ._SENT The_DT SV40_NP promoter_NN was_VBD repressed_VBN greater_JJR than_IN 90_CD %_NN whether_IN the_DT MLV_NP PBS_NP was_VBD placed_VBN upstream_RB or_CC downstream_RB of_IN the_DT promoter_NN ._SENT The_DT hUbiqC_NN promoter_NN was_VBD repressed_VBN greater_JJR than_IN 60_CD %_NN ,_, the_DT hEF-1a_NN promoter_NN was_VBD repressed_VBN greater_JJR than_IN 75_CD %_NN ,_, and_CC the_DT mPGK_NN promoter_NN was_VBD repressed_VBN greater_JJR than_IN 80_CD %_NN ._SENT In_IN comparison_NN ,_, the_DT MN_NN 